Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
DocMorris ( (CH:DOCM) ) has provided an update.
DocMorris AG has successfully achieved its 2024 sales and earnings targets, with a notable increase in electronic prescription adoption in Germany. The company anticipates a 50% growth in Rx sales in Q1 2025 and plans a capital increase of CHF 200 million to support strategic goals, including new customer acquisition and sustainability initiatives. The Non-Rx business in Germany has reached profitability, and TeleClinic has significantly increased its sales and earnings. DocMorris also reported a 67% reduction in CO2e emissions, aligning with its sustainability goals.
More about DocMorris
DocMorris AG operates in the pharmaceutical industry, primarily focusing on the sale of prescription (Rx) and non-prescription (Non-Rx) drugs. The company has established itself as a leader in the electronic prescription market in Germany and is expanding its customer base through innovative solutions like CardLink.
YTD Price Performance: 5.71%
Average Trading Volume: 128,518
Technical Sentiment Consensus Rating: Buy
Current Market Cap: CHF290.9M
For an in-depth examination of DOCM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue